Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Non Small Cell Lung Cancer
97%
Epidermal Growth Factor Receptor
84%
Reactive Oxygen Metabolite
52%
Lung Adenocarcinoma
52%
Neoplasm
30%
Biological Marker
29%
Overall Survival
28%
Afatinib
26%
Progression Free Survival
22%
Cytokine
21%
Rose
18%
Placebo
18%
Gefitinib
18%
Immune Checkpoint Inhibitor
17%
Osimertinib
16%
Chronic Obstructive Lung Disease
15%
Protein Tyrosine Kinase Inhibitor
14%
Adult Respiratory Distress Syndrome
14%
Effusion
14%
Cisplatin
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Inflammation
13%
Antiinflammatory Activity
12%
Immunotherapy
12%
Hypoxia Inducible Factor 1
11%
Phosphotransferase
10%
Combination Therapy
10%
Small Cell Lung Cancer
10%
Therapeutic Effect
9%
Allergic Asthma
9%
Ribavirin
9%
I Kappa B Kinase Inhibitor
9%
Survival Time
9%
Gelatinase B
9%
Trachea Stenosis
9%
Lung Tuberculosis
9%
Squamous Cell Lung Carcinoma
9%
Immunoglobulin E
9%
Human Respiratory Syncytial Virus
9%
Pemetrexed
9%
Thymidylate Synthase
9%
Beta2 Agonist
9%
Chemokine
9%
Interstitial Lung Disease
9%
Cohort Study
9%
Recurrent Disease
8%
Cancer Mortality
8%
Vasculotropin
7%
Dyspnea
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
91%
Lung Cancer
85%
Epidermal Growth Factor Receptor
66%
Reactive Oxygen Species
62%
Lung Adenocarcinoma
43%
Neoplasm
27%
Afatinib
26%
Biological Marker
22%
Overall Survival
20%
Lung
20%
Immune Checkpoint Inhibitor
20%
Ribavirin
18%
Placebo
18%
Gefitinib
18%
Effusion
14%
Pemetrexed
14%
Diagnostic Marker
14%
Cancer-Related Fatigue
14%
Immunotherapy
13%
Progression Free Survival
12%
Hazard Ratio
11%
Sensitivity and Specificity
11%
Osimertinib
11%
Chronic Obstructive Pulmonary Disease
11%
Cisplatin
10%
Predictive Marker
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Hypoxia Inducible Factor 1
9%
Adenoviridae
9%
Bronchus Carcinoid
9%
Acute Respiratory Distress Syndrome
9%
Squamous Cell Lung Carcinoma
9%
Cryotherapy
9%
Mycobacterium Tuberculosis
9%
Real Time Polymerase Chain Reaction
9%
Therapy Effect
9%
Gelatinase B
9%
Propylthiouracil
9%
Human Respiratory Syncytial Virus
9%
Cancer Mortality
9%
Survival Time
9%
Cryptorchism
9%
Pneumothorax
9%
Ehlers Danlos Syndrome
9%
Lamellar Body
9%
Pulmonary Capillary Hemangiomatosis
9%
Pulmonary Hemorrhage
9%
Thymidylate Synthase
9%
Base Excision Repair
9%
Carcinoid
9%